Your browser doesn't support javascript.
loading
Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.
Coomans de Brachène, Alexandra; Castela, Angela; Op de Beeck, Anne; Mirmira, Raghavendra G; Marselli, Lorella; Marchetti, Piero; Masse, Craig; Miao, Wenyan; Leit, Silvana; Evans-Molina, Carmella; Eizirik, Decio L.
Affiliation
  • Coomans de Brachène A; ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Castela A; ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Op de Beeck A; ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Mirmira RG; Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Marselli L; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Marchetti P; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Masse C; Nimbus Therapeutics, Cambridge, Massachusetts, USA.
  • Miao W; Nimbus Therapeutics, Cambridge, Massachusetts, USA.
  • Leit S; Nimbus Therapeutics, Cambridge, Massachusetts, USA.
  • Evans-Molina C; Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Eizirik DL; ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Diabetes Obes Metab ; 22(10): 1827-1836, 2020 10.
Article in En | MEDLINE | ID: mdl-32476252

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Insulin-Secreting Cells Limits: Humans Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Insulin-Secreting Cells Limits: Humans Language: En Year: 2020 Type: Article